ERX Eirx Therap.

RNS Number:1455O
EiRx Therapeutics PLC
15 February 2008

                             EIRX THERAPEUTICS  PLC

                          ( "EiRx" or "the Company" )



                                Funding package



The Directors of Eirx Therapeutics plc are pleased to announce that EiRx has
agreed in principle a funding package designed to provide working capital to
fund the Company until at least 31 December 2008 comprising a placing of shares,
convertible loan stock and an enlarged bank facility along with some short term
funding.



The details of the funding package are being finalised and will be announced no
later than Thursday 21 February 2008.



For further information, please contact:


EiRx Therapeutics plc                                 +353 (0)21 432 0847
Colin Telfer PhD, Chief Executive Officer
Grant Thornton Corporate Finance                      +44 (0)20 7383 5100
Philip Secrett / Colin Aaronson







About EiRx

EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing
cutting-edge targeted therapies for the treatment of cancer.  EiRx is
headquartered in Cork, Ireland, conducts drug discovery from its laboratories in
Cork and in Aberdeen, Scotland.  The Company has an initial focus on tumours
arising due to anomalies in apoptosis and cellular growth regulatory pathways,
with particular relation to breast and colorectal tumours, currently two of the
four leading causes of death from cancer world-wide.



EiRx is built on leading scientific expertise in the areas of apoptosis biology,
cancer pathway biology, biomarker technologies and the metabolic basis of drug
resistance in tumours.  It has established technical capabilities in target
identification, validation and cell-based screening, and is combining unique
resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional
genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic
cellular screening technology to create a product development engine
specialising in discovery and development of small-molecule targeted cancer
therapies and the discovery and validation of cancer biomarkers.





For further information please see our website at http://www.eirx.com








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCZGGMZVKRGRZM

Eirx Therapeutics (LSE:ERX)
Historical Stock Chart
From May 2024 to Jun 2024

Eirx Therapeutics (LSE:ERX)
Historical Stock Chart
From Jun 2023 to Jun 2024